- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
CSC acquires majority interest in Danish info tech
Looking beyond the U.S. medical market, healthcare consulting firm Computer Sciences Corporation (CSC) has acquired 60% of the Danish information technology company Scandinavian Healthcare Informatics (ScandiHealth). Because ScandiHealth provides IT
Looking beyond the U.S. medical market, healthcare consulting firm Computer Sciences Corporation (CSC) has acquired 60% of the Danish information technology company Scandinavian Healthcare Informatics (ScandiHealth). Because ScandiHealth provides IT services for the Association of County Councils in Denmark, an organization that acts as spokesperson for all Danish county councils in central government matters such as hospital administration, it proved an attractive buy for CSC. Through this acquisition, CSC assumes responsibility for ScandiHealth's long-term contracts with Danish hospitals and thus will become the largest healthcare IT services provider in Denmark. The firm plans to use the Danish market as a springboard to expand its presence in healthcare in other European countries. Terms of the acquisition were not disclosed.
Study Reaffirms Low Risk for csPCa with Biopsy Omission After Negative Prostate MRI
December 19th 2024In a new study involving nearly 600 biopsy-naïve men, researchers found that only 4 percent of those with negative prostate MRI had clinically significant prostate cancer after three years of active monitoring.
Study Examines Impact of Deep Learning on Fast MRI Protocols for Knee Pain
December 17th 2024Ten-minute and five-minute knee MRI exams with compressed sequences facilitated by deep learning offered nearly equivalent sensitivity and specificity as an 18-minute conventional MRI knee exam, according to research presented recently at the RSNA conference.
Can Radiomics Bolster Low-Dose CT Prognostic Assessment for High-Risk Lung Adenocarcinoma?
December 16th 2024A CT-based radiomic model offered over 10 percent higher specificity and positive predictive value for high-risk lung adenocarcinoma in comparison to a radiographic model, according to external validation testing in a recent study.
